Atlanta, Ga., June 22, 2026 (GLOBE NEWSWIRE) — Outdoor Holding Company (Nasdaq: POWW, POWWP) (“OHC,” “we,” “us,” “our” or the “Company”), the owner of GunBroker.com, the largest online marketplace dedicated to firearms, hunting, shooting, and related products, today reported its financial results for its fourth fiscal quarter and year ended March 31, 2026. Fourth Quarter Fiscal 2026 vs. Fourth Quarter Fiscal 2025Revenue increased 10.1% to $13.9 million from $12.6 million Gross profit rose to $12.2 million from $11.0 million Gross profit margin increased slightly to 87.6% from 87.5% Operating expenses decreased to $15.1 million from $38.0 million Loss from continuing operations of $(2.7) million, compared to last year’s loss from continuing operations of $(27.0) million Net loss attributable to common shareholders of $(1.5) million...

PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional positive data from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, will be shared in a late breaking oral presentation at the International Congress of Children’s Bone Health (ICCBH) 2026 taking place in Montreal, Canada on June 27-30, 2026. BridgeBio will also share an oral presentation and four posters at the meeting highlighting quality of life, early intervention research, observational study findings, and educational resources through MyAchonJourney for individuals with achondroplasia and related skeletal...

BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. The announcement comes after a series of favorable policy changes, the latest of which is a recently issued policy covering 2 million members in South Carolina allowing for coverage of SWIFT, in addition to various other increases in Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) patients. With this update, eight major payers and the US Department of Veterans Affairs now either cover or include policy...

Vancouver, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) — Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) (“Deep Sea Minerals” or the “Company“), a seabed mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, today welcomed the G7 leaders’ declaration on securing supply chains for critical minerals, which underscores the strategic importance of diversified, transparent, and resilient critical minerals supply chains. The declaration highlights the needs for G7 members and partners to reduce supply-chain vulnerabilities, mobilize public and private capital, support responsible production and processing, improve market transparency, and strengthen cooperation across critical minerals value chains. Deep Sea Minerals believes the...

Company’s presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the UAE Genome Program PHILADELPHIA, June 22, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it will participate in the 2026 Bio International Conference, being held on June 22-25, 2026, in San Diego, California. Dr. Faisal Mehmud, Chief Medical Officer of Medicus, will deliver a company presentation highlighting recent clinical, regulatory and strategic advancements across the Company’s development portfolio. The presentation will provide...

WINTER PARK, Fla., June 22, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the tokenization ecosystem for all real-world assets beginning with commodities, today announced the distribution of the third yield payment for GLDY, its gold-backed, yield-bearing tokenized security, occurred on June 18th, 2026. The distribution covers the period from May 1st through May 31st, 2026. Yield Distribution Details GLDY’s real-world yield is generated through Streamex’s institutional gold leasing program, with proceeds from the program distributed to GLDY holders in the form of additional GLDY tokens monthly. Each GLDY token is currently earning an annualized yield of 3.5%. For the month of May, 8.94674 GLDY (8.94674 oz’s of gold) was...

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted Palvella remains on track to complete the NDA submission in the second half of 2026 QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and standard of care for the estimated more than 30,000 individuals with microcystic lymphatic malformations in the U.S. WAYNE, Pa., June 22, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today...

Conference Call to Be Held on July 23, 2026 at 2:00pm ET NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced that it will release its earnings for the second quarter of 2026 on Wednesday, July 22, 2026 after market close. The Company’s executive management team, led by Marc Holliday, Chairman and Chief Executive Officer, will host a conference call and audio webcast on Thursday, July 23, 2026 at 2:00pm ET to discuss the financial results. Simultaneous with the earnings release, supplemental data will be made available in the Investors section of the SL Green Realty Corp. website at https://slgreen.com/ under “Financial Reports”. The live conference call will be webcast in listen-only mode and a replay will be available in the Investors section...

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi [NXP100]) and also enhances the oncology product pipeline with the in-licensing of a paradox breaker BRAF inhibitor (BRAFi [NXP200]) for the treatment of BRAF-mutated malignancies. NXP100 (HSK39297): A once-daily, oral CFBi in late-stage development for the treatment of complement-mediated diseases. Current development status in China includes: Two Marketing Authorization Applications (MAAs) are under review for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH); The applications seek approvals for NXP100 for the treatment of PNH in treatment-naive patients and in patients who failed treatment with a Complement protein 5 (C5)...